Document:

Contribution Agreement

 Exhibit 10.12 
  
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested 
 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 230.406 
  
 CONTRIBUTION AGREEMENT 
  
 This Contribution Agreement (this “Agreement”) is entered into as of August 31st, 2000 (the “Effective Date”) by and between CryoCor, Inc., a Delaware corporation (the Company”),
and Cryogen, Inc., a California corporation (“Cryogen”). 
  
 BACKGROUND 
  
 A.
Cryogen desires to provide for the initial capitalization of the Company. 
  
 B. In accordance with the terms and conditions of this Agreement, Cryogen desires to contribute to the Company certain assets and intellectual property rights for the development of products (“Company
Products”) for use in performing cardiac or vascular ablation for the treatment of cardiac arrhythmias in consideration of the issuance by the Company to Cryogen of a specified number of shares of the Company’s Series A Convertible
Preferred Stock (the “Series A Preferred Stock”) and the Company’s Common Stock (the “Common Stock”). 
  
 C. Following the Closing (as hereinafter defined) of the transactions contemplated hereby, Cryogen desires and intends to distribute (the
“Distribution”) the Company Common Shares (as hereinafter defined) and the Company Series A Shares (as hereinafter defined) to its holders of equity securities, including option holders and warrant holders (if an when exercised), in
proportion to their ownership of the common stock and preferred stock of Cryogen, as the case may be, on an as-converted basis. 
  
 D. Simultaneously with the Closing of the transactions contemplated hereby, the Company desires to issue shares of Series B Preferred Stock as set
forth in that certain term sheet (the “Term Sheet”), dated June 16, 2000 between Cryogen and MPM Capital (the “Series B Financing”). 
  
 AGREEMENT 
  
 Now, therefore, in consideration of the foregoing recitals, the mutual promises set forth in this Agreement, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement agree as follows: 
  
 1. AGREEMENT TO ISSUE STOCK AND GRANT RIGHTS. 
  
 1.1 Agreement to Issue Stock. 
  
 (a) Authorization. On the date of the Closing, the Company shall have authorized the issuance, pursuant to the terms and conditions of this
Agreement, of a total of 1,604,166 shares of Common Stock and a total of 5,645,834 shares of Series A Preferred Stock. The Common Stock and the Series A Preferred Stock shall have the rights, preferences, privileges and restrictions as set forth in
the Amended and Restated Certificate of Incorporation of the Company in the form of Exhibit A hereto (the “Restated Certificate”). 
  

 1. 

 (b) Shares. Subject to the terms and conditions of this Agreement, on the date of the Closing,
the Company shall issue to Cryogen, and Cryogen agrees to accept from the Company, (A) 1,604,166 shares of Common Stock (the “Company Common Shares”) and (B) 5,645,834 shares of Series A Preferred Stock (the “Company Series
A Shares;” and together with the Company Common Shares, the “Shares”). 
  
 1.2 Agreement to Contribute Assets and Grant Rights, Etc. 
  

(a) Assets and Other Items to be Contributed and Rights to be Granted by Cryogen. Subject to the terms and conditions of this Agreement, on the
date of the Closing, Cryogen shall: 
  
 (i) sell,
assign, transfer, convey and deliver to the Company all of Cryogen’s right, title and interest in and to the assets, rights and properties set forth on Exhibit B hereto (the “Contributed Assets”) and the clinical
development products set forth on Exhibit E hereto (the “Contributed Clinical Development Products”), free and clear of all liens, encumbrances and security interests; 
  
 (ii) grant a license to the Company (the “License”)
for certain intellectual property rights of Cryogen with respect to the development of the Company Products (the “Licensed Technology”) as set forth in the License Agreement attached hereto as Exhibit C (the “License
Agreement”); 
  
 (iii) enter into a Research and
Development Agreement with the Company substantially in the form attached hereto as Exhibit D (the “Development Agreement;” the License Agreement and the Development Agreement are collectively referred to herein as the
“Related Agreements”); 
  
 (iv) sell,
assign, transfer, convey and deliver to the Company, and the Company shall assume from Cryogen, all of Cryogen’s right, title and interest in and to and all obligations under the agreements and contracts for the production of certain molds
listed on Exhibit F hereto (the “Purchased Molds Contracts”) and the right to delivery of the molds produced thereunder, free and clear of all liens, encumbrances and security interests; and 
  
 (v) sell, assign, transfer, convey and deliver to the Company all of
Cryogen’s right, title and interest in and to the raw materials to be used to develop and manufacture the Company Products (the “Development Raw Materials”), free and clear of all liens, encumbrances and security interests.

  
 2. CLOSING; DELIVERY. 
  
 2.1 Closing. 
  
 (a) Closing. The closing of the transactions contemplated hereby
shall be held at the offices of Brobeck, Phleger & Harrison LLP, 12390 El Camino Real, San Diego, CA 92130 at 11:00 a.m. on August 24, 2000, or at such other time and place as the Company and Cryogen may mutually agree upon (the
“Closing”). 
  

 2. 

 (b) Deliveries. At the Closing, the Company shall deliver to Cryogen certificates representing
the Shares to be issued to Cryogen at the Closing against delivery of a counterpart executed by Cryogen of each of the License Agreement, the Development Agreement and such assignments, bills of sale and other instruments as shall be necessary to
evidence the assignment, transfer, conveyance and delivery to the Company of the Contributed Assets, the Contributed Clinical Development Products, the Purchased Molds Contracts and the Development Raw Materials and the assumption by the Company of
the CryoCor Employee Liabilities (as defined below), the Raw Materials Liability (as defined below), and the liabilities and obligations under the Purchased Mold Contracts (the “Assignment and Assumption Documents”). In addition,
within seven (7) days following the Closing, the Company shall (i) pay the sum of $[...***...] in cash to Cryogen as reimbursement for amounts actually heretofore paid by Cryogen to the vendors of the Purchased Molds Contracts under the terms
of the Purchased Molds Contracts; (ii) pay to Cryogen the purchase price for the Development Raw Materials (estimated as of the date hereof to be approximately $[...***...]) (the “Raw Materials Liability”), which such purchase
price shall be invoiced by Cryogen to the Company promptly after the Closing; and (iii) reimburse Cryogen for the fees, costs and expenses charged by Trinet Employer Group, Inc. (“Trinet”) and actually paid or payable by Cryogen
with respect to each of the CryoCor Employees (as such term is defined in Section 6.3(a) hereof), including, costs and expenses for payroll, payroll taxes, administrative fees, overtime and benefits charged by Trinet, for the period beginning
12:00 p.m. California time on August 4, 2000 through the date of the Closing (the “CryoCor Employee Liabilities”), which such fees, costs and expenses will be invoiced by Cryogen to the Company promptly after the Closing.
Notwithstanding the foregoing, for purposes of this Section 2.1(b), “CryoCor Employees” shall not be deemed to include any CryoCor Employee who elects not to become an employee of the Company. 
  
 3. COMPANY REPRESENTATIONS AND WARRANTIES. The Company hereby
represents and warrants to Cryogen as follows: 
  
 3.1
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to own its properties
and assets and to carry on its business as now conducted and as presently proposed to be conducted. The Company has filed to become qualified to transact business as a foreign corporation in the State of California. 
  
 3.2 Power and Capacity; Authorization. The company has the necessary
corporate power and authority to enter into, execute and deliver this Agreement and the Related Agreements, to perform its obligations hereunder and thereunder to consummate the transactions contemplated hereby and thereby. The execution and
delivery of this Agreement and the Related Agreements and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized by all required corporate action of the Company. This Agreement and the Related
Agreements have been executed and delivered by the Company and constitute legal and binding agreements enforceable against the Company in accordance with their respective terms (subject, as to the enforcement of remedies, to applicable bankruptcy,
reorganization, insolvency, moratorium and similar laws affecting creditors’ rights, and, with respect to the remedy of specific performance, equitable doctrines applicable thereto). 
  
 * Confidential Treatment Requested 
  

 3. 

 3.3 Capitalization. Immediately prior to the Closing, the authorized capital stock of the Company
consists of the following: 
  
 (a) Common Stock. A total
of 30,000,000 authorized shares of Common Stock, $0.001 par value, none of which are issued and outstanding. 
  
 (b) Preferred Stock. A total of 15,000,000 authorized shares of Preferred Stock, $0.001 par value, 5,645,830 of which are designated Series A
Preferred Stock and none of which are issued and outstanding and 4,861,111 of which are designated Series B Preferred Stock and none of which are issued outstanding. 
  
 (c) Options, Warrants, Reserved Shares. Except as set forth on Schedule 3.3 hereto and for (i) the conversion
privileges of the Series A Preferred Stock to be issued hereunder and the Series B Preferred Stock to be issued pursuant to the Series B Financing and (ii) 1,750,000 shares of Common Stock reserved for issuance under the Company’s 2000 Stock
Option Plan, there are no options, warrants, conversion privileges or other rights, or agreements with respect to the issuance thereof, presently outstanding to purchase any of the capital stock of the Company. 
  
 3.4 Consents; No Conflicts. The execution, delivery and performance of
this Agreement and the Related Agreements by the Company shall not: (a) conflict with or result in a material breach of or default under the Company’s Restated Certificate or Bylaws; (b) result in a violation of any law, rule, ordinance,
regulation, order, judgment or decree by which the Company is bound; or (c) conflict with or result in a material breach of or default under any mortgage, lien, lease, license, permit, agreement, contract or instrument to which the Company is a
party or by which the Company is bound, which conflict, breach or default would have a material adverse effect on the Company’s ability to perform its obligations under this Agreement. 
  
 3.5 Actions and Proceedings. There are no outstanding orders,
judgments, injunctions, awards or decrees of any court, governmental or regulatory body or arbitration tribunal against or involving the Company. There are no actions, suits or claims or legal, administrative or arbitral proceedings or, to the
Company’s knowledge, investigations (whether or not the defense thereof or liabilities in respect thereof are covered by insurance) pending or, to the Company’s knowledge, threatened against or involving the Company. 
  
 3.6 Valid Issuance of Stock. 
  
 (a) The Shares, when issued, sold and delivered in accordance with
the terms of this Agreement, shall be duly and validly issued, fully paid and non-assessable. 
  
 (b) All outstanding shares of the capital stock of the Company are duly and validly issued, fully paid and non-assessable. 
  
 3.7 Liabilities. Except for indebtedness and reimbursements owed to Cryogen after the Closing as provided in
Section 2.1(b) hereof and amounts payable to the vendors of the Purchased Molds Contracts, the Company has no indebtedness for borrowed money that the Company has directly or indirectly created, incurred, assumed, or guaranteed, or with
respect to which the Company has otherwise become directly or indirectly liable. 
  

 4. 

 3.8 Exempt Offering. Based in part upon on Cryogen’s representations in Section 4, the
offer and sale of the Shares to Cryogen pursuant to this Agreement are exempt from the registration requirements of Section 5 of the Securities Act of 1933, as amended (the “Act”), by virtue of Section 4(2) thereof and from
the qualification requirements of the California Corporate Securities Law of 1968, as amended, by virtue of Section 25102(f) thereof. 
  
 3.9 Full Disclosure. All documents and other papers delivered by or on behalf of the Company in connection with this Agreement and the transactions
contemplated hereby are true and complete. No representation or warranty of the Company contained in this Agreement, and to the Company’s knowledge, no document or other paper finished by or on behalf of the Company to Cryogen (or any of its
agents) pursuant to this Agreement or in connection with the transactions contemplated hereby, taken as a whole, contains an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the
statements made, in the context in which made, not false or misleading. 
  
 4. REPRESENTATIONS AND WARRANTIES OF CRYOGEN TO THE COMPANY. Cryogen represents and warrants to the Company as follows: 
  
 4.1 Organization and Qualification. Cryogen is a corporation duly incorporated, validly existing and in good standing under the laws of the State
of California and has all requisite corporate power and authority to own its assets and properties and to carry on its business as now being and as heretofore conducted. 
  
 4.2 Power and Capacity; Authorization. Cryogen has the necessary corporate power and authority to enter into, execute
and deliver this Agreement and the Related Agreements, to perform its obligations hereunder and thereunder to consummate the transactions contemplated hereby and thereby. The execution and delivery of this Agreement and the Related Agreements and
the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized by all required corporate action of Cryogen. This Agreement and the Related Agreements have been executed and delivered by Cryogen and
constitute legal and binding agreements enforceable against Cryogen in accordance with their respective terms (subject, as to the enforcement of remedies, to applicable bankruptcy, reorganization, insolvency, moratorium and similar laws affecting
creditors’ rights, and, with respect to the remedy of specific performance, equitable doctrines applicable thereto). 
  
 4.3 Consents; No Conflicts. Except with respect to that certain Subordinated Loan and Security Agreement dated March 25, 1998 between Cryogen and
Comdisco, Inc. and all instruments executed in connection therewith, that certain Master Lease Agreement dated August 25, 1997 between Cryogen and Comdisco, Inc. and all instruments executed in connection therewith and that certain Master Loan and
Security Agreement dated January 28, 1999 between Cryogen and Lease Management Services, Inc. and all instruments executed in connection therewith (collectively, the “Debt Documents”), with respect to which Cryogen will
obtain waivers and/or consents at or prior to the Closing pursuant to Section 7.1(k) hereof, the execution, delivery and performance of this Agreement and the Related Agreements by Cryogen 

  

 5. 

 
shall not: (a) conflict with or result in a breach of or default under Cryogen’s Articles of Incorporation or Bylaws, as such may have been amended
through the date hereof; (b) result in a violation of any law, rule, ordinance, regulation, order, judgment or decree by which Cryogen is bound; or (c) conflict with or result in a breach of or default under any mortgage, lien, lease, license,
permit, agreement, contract or instrument to which Cryogen is a party or by which Cryogen is bound, which conflict, breach or default would have a material adverse effect on Cryogen’s ability to perform its obligations under this Agreement.

  
 4.4 Actions and Proceedings. There are no outstanding
orders, judgments, injunctions, awards or decrees of any court, governmental or regulatory body or arbitration tribunal against or involving Cryogen with respect to the Licensed Technology. Except as set forth on Schedule 4.4 hereto, there
are no actions, suits or claims or legal, administrative or arbitral proceedings or, to Cryogen’s knowledge, investigations (whether or not the defense thereof or liabilities in respect thereof are covered by insurance) pending or, to
Cryogen’s knowledge, threatened against or involving Cryogen with respect to the Licensed Technology. 
  
 4.5 Intellectual Property. Except for liens and encumbrances arising under the Debt Documents or as otherwise set forth on Schedule 4.5
hereto, Cryogen owns all right, title and interest in and to the Contributed Assets and all of the Licensed Technology to be licensed (or sublicensed) by Cryogen to the Company pursuant to the License Agreement, free and clear of all liens and
encumbrances of third parties. Cryogen has not granted any licenses or other rights to any third party with respect to the Contributed Assets or any Licensed Technology. Except for the matters set forth on Schedule 4.4 hereto, (i) Cryogen has
not received any written notice or claim challenging its rights with respect to the Contributed Assets or any Licensed Technology; (ii) there are no actions, suits, or proceedings pending or, to the knowledge of Cryogen, threatened, based on an
allegation that the use or practice of the Contributed Assets or any of the Licensed Technology by Cryogen infringes or misappropriates the patents, copyrights, trade secrets, trademarks or other intellectual property of any third party; and (iii)
to the knowledge of Cryogen, the use or practice by Cryogen of the Contributed Assets or the Licensed Technology has not infringed or resulted in the misappropriation of any patent, copyright, trade secret or other intellectual property rights of
any third party. 
  
 4.6 Full Disclosure. All documents and
other papers delivered by or on behalf of Cryogen in connection with this Agreement and the transactions contemplated hereby are true and complete. No representation or warranty of Cryogen contained in this Agreement, and to Cryogen’s
knowledge, no document or other paper furnished by or on behalf of Cryogen to the Company (or any of its agents) pursuant to this Agreement or in connection with the transactions contemplated hereby, taken as a whole, contains an untrue statement of
a material fact or omits to state a material fact required to be stated therein or necessary to make the statements made, in the context in which made, not false or misleading. 
  
 4.7 Investment Representations. 
  
 (a) Investigation; Economic Risk. Cryogen acknowledges it has had an opportunity to discuss the business, affairs
and current prospects of the Company with its officers; Cryogen acknowledges having had access to information about the Company that it has requested; and Cryogen acknowledges that it is able to fend for itself in the transactions contemplated by
this Agreement and has the ability to bear the economic risks of its investment pursuant to this Agreement. 
  

 6. 

 (b) Purchase for Own Account. The Shares and any other of the Company’s securities acquired
by Cryogen pursuant to this Agreement shall be acquired for its own account, not as a nominee or agent, and, except in connection with the Distribution (which Distribution Cryogen shall effect in compliance with all applicable federal and state
securities laws, rules and regulations), not with a view to or in connection with the sale or distribution of any part thereof. 
  
 (c) Exempt from Registration; Restricted Securities. Cryogen understands that the Shares and any other of the Company’s securities acquired
by Cryogen pursuant to this Agreement shall not be registered under the Act, on the ground that the sale provided for in this Agreement is exempt from registration under of the Act, and that the reliance of the Company on such exemption is
predicated in part on Cryogen’s representations set forth in this Agreement. In addition, Cryogen shall effect the Distribution in compliance with all applicable federal and state securities laws, rules and regulations. Cryogen understands that
the Shares and any other of the Company’s securities acquired by Cryogen pursuant to this Agreement are restricted securities within the meaning of Rule 144 under the Act. Cryogen further understands that the Shares and any other of the
Company’s securities acquired by Cryogen pursuant to this Agreement are not registered and must be held indefinitely unless they are subsequently registered or an exemption from such registration is available. 
  
 5. AGREEMENTS REGARDING SHARES. The Company and Cryogen agree as
follows: 
  
 5.1 Restrictive Legends. Each certificate
representing the Shares and any other securities issued in respect of any of the foregoing upon any stock split, stock dividend, recapitalization, merger or similar event shall be stamped or otherwise imprinted with a legend substantially in the
following form: 
  
 THE SECURITIES REPRESENTED HEREBY HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR
RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. 
  
 5.2 Removal of Restrictive Legend. The legend set forth above shall be removed by the Company from any certificate evidencing the Shares or any
other of the Company’s securities acquired by Cryogen pursuant to this Agreement upon delivery to the Company of an opinion by counsel, reasonably satisfactory to the Company, if requested by the Company that a registration statement under the
Act is at that time in effect with respect to the legended security or that such security can be freely transferred in a public sale without such a registration statement being in effect and that such transfer shall not jeopardize the exemption or
exemptions from registration pursuant to which the Company issued the Shares. 
  

 7. 

 6. OTHER AGREEMENTS. 
  
 6.1 Further Assurances. From time to time after the Closing, Cryogen shall execute and deliver to the Company such
instruments as may be reasonably requested by the Company in order to more fully implement the transaction contemplated hereby. 
  
 6.2 Confidentiality Obligations. 
  
 (a) Any party to this Agreement (the “Disclosing Party”) may from time to time disclose Confidential Information to the other
party to this Agreement (each a “Recipient”). “Confidential Information” is all nonpublic information concerning the unpatented intellectual property (and any and all rights therein or applications thereof), product
specifications, any and all know-how, methods and processes with respect to products and marketing plans, marketing strategies and general market data of the Disclosing Party which is conveyed to the Recipient orally or in tangible form. Recipient
shall keep in confidence and trust and shall not disclose or disseminate, or permit any employee, agent or other person working under Recipient’s direction to disclose or disseminate, the existence, source, content or substance of any
Confidential Information to any other person or entity. Recipient shall use Confidential Information of the Disclosing Party only as necessary for the performance of this Agreement and the Related Agreements; provided, however, a Recipient may
disclose Confidential Information to one or more potential financing sources upon the prior written consent of the Disclosing Party which consent shall not be unreasonably withheld or delayed. Recipient shall employ at least the same methods and
degree of care, but no less than a reasonable degree of care, to prevent disclosure of the Confidential Information as Recipient employs with respect to its own confidential trade secrets and proprietary information. Recipient’s employees and
independent contractors shall be given access to the Confidential Information only on a need-to-know basis, and only if they have executed a form of nondisclosure agreement with Recipient which imposes a duty to maintain the confidentiality of the
Confidential Information that is at least as restrictive as the terms of this Section 6.2. 
  
 (b) The commitments in this Section 6.2 shall not impose any obligations on Recipient with respect to any portion of the received
information which: (i) is now generally known by or available to the public or which hereafter, through no act or failure to act on the part of Recipient, becomes generally known or available in the public domain; (ii) is furnished to Recipient by a
third party without restriction on disclosure and without a breach by such third party of any confidentiality undertaking with respect thereto; or (iii) is required to be disclosed by operation of law or by an instrumentality of the government,
including but not limited to any court, tribunal or administrative agency; provided that, in the case of any disclosure required by court order, the Recipient shall give the Disclosing Party as much advance notice as is reasonably practicable under
the circumstances so as to permit the Disclosing Party to seek a protective order. 
  
 (c) Other than confidentiality and non-disclosure agreements contained in the Related Agreements, this Section 6.2 terminates and supersedes all confidentiality and 

  

 8. 

 
nondisclosure agreements executed by the parties to this Agreement prior to the date of this Agreement in connection with the transactions contemplated by
this Agreement. The terms of this Section 6.2 shall control in the event of a conflict between this Section 6.2 and the confidentiality and non-disclosure agreements contained in the Related Agreements (or any of them). 
  
 (d) The obligations of the parties hereto under this Section
6.2 shall survive indefinitely. 
  
 6.3
Non-Solicitation. Except for those current Cryogen employees listed on Schedule 6.3 hereto (the “CryoCor Employees”) and [...***...], neither the Company nor any of its Affiliates shall solicit, hire or engage,
whether as an employee, consultant, independent contractor or otherwise, any person who is or was an employee of Cryogen or any of its Affiliates or actively induce or otherwise assist any person or entity in soliciting, hiring or engaging, whether,
as an employee, consultant, independent contractor or otherwise, any person who is or was an employee of Cryogen or any of its Affiliates without the prior written consent of Cryogen; provided, however, that, if (i) any such person has not been so
employed or engaged by Cryogen or any of its Affiliates for a consecutive period of two (2) years or more and (ii) neither the Company nor any of its Affiliates shall have solicited or actively induced or otherwise assisted in soliciting for the
employment or engagement as a consultant or independent contractor of such person while still employed or engaged by Cryogen or any of its Affiliates, then the Company may hire such person without violating the terms of this Section 6.3(a);
and, provided further, that this Section 6.3(a) shall be of no force and effect beginning ninety (90) days after the consummation of a Change of Control of Cryogen. 
  
 (a) Neither Cryogen nor any of its Affiliates shall solicit, hire or engage, whether as an employee, consultant,
independent contractor or otherwise, any of the CryoCor Employees or actively induce or otherwise assist any person or entity in soliciting, hiring or engaging, whether, as an employee, consultant, independent contractor or otherwise, any of the
CryoCor Employees without the prior written consent of the Company; provided, however, that, if (i) any such CryoCor Employee has not been so employed or engaged by the Company or any of its Affiliates for a consecutive period of two (2) years or
more and (ii) neither Cryogen nor any of its Affiliates shall have solicited or actively induced or otherwise assisted in soliciting for the employment or engagement as a consultant or independent contractor of any such CryoCor Employees while still
employed or engaged by the Company or any of its Affiliates, then Cryogen may hire such person without violating the terms of this Section 6.3(b); and, provided further, that this Section 6.3(b) shall be of no force and effect
beginning ninety (90) days after the consummation of a Change of Control of the Company. 
  
 (b) For purposes of this Agreement, “Affiliate” means a corporation, company, or other legal entity now or hereinafter controlling, controlled by or under common control with a party hereto, for so
long as such ownership or control exists. For the purposes of this definition, control shall refer to a greater than 50% interest in the right to make decisions for such entity (e.g., greater than 50% ownership of the voting shares or other voting
securities of such entity). Notwithstanding anything to the contrary contained herein, “Affiliate” shall not include (i) in the case of Cryogen, the Company and (ii) in the case of the Company, Cryogen. For purposes of this Agreement, a
“Change of Control” shall mean: (x) the liquidation, winding 
  
 * Confidential Treatment Requested 
  

 9. 

 up or dissolution of Cryogen: (y) a merger, consolidation, reorganization, recapitalization or other transaction or
series of related transactions which results in the holders of the outstanding voting securities of Cryogen (determined immediately prior to such transaction) owning less than a majority of the outstanding voting securities of the surviving
corporation (determined immediately following such transaction); or (z) any sale or transfer by Cryogen of all or substantially all its assets. 
  
 7. CONDITIONS TO CRYOGEN’S OBLIGATIONS AT THE CLOSING. 
  
 7.1 Conditions to Closing. The obligations of Cryogen under this Agreement are subject to the fulfillment, to the
satisfaction of Cryogen on or prior to the Closing, of the following conditions: 
  
 (a) Representations and Warranties Correct. The representations and warranties made by the Company in Section 3 of this Agreement shall be true and correct when made, and shall be true and correct as of
the date of the Closing with the same force and effect as if they had been made on and as of such date. 
  
 (b) Performance of Obligations. The Company shall have performed and complied with all agreements, obligations and conditions contained in this
Agreement that are required to be performed or complied with by it on or before the Closing and shall have obtained all approvals, consents and qualifications necessary to complete the purchase and sale described herein. 
  
 (c) Proceedings and Documents. All corporate and other proceedings in
connection with the transactions contemplated by this Agreement and all documents and instruments incident to such transactions shall be satisfactory in substance and form to Cryogen, and Cryogen shall have received all such counterpart originals or
certified or other copies of such documents as it may reasonably request. 
  
 (d) Consents and Waivers. The Company shall have obtained any and all consents and waivers necessary or appropriate for consummation of the transactions contemplated by this Agreement, including any necessary
governmental or regulatory notices and approvals. 
  
 (e)
Restated Certificate of Incorporation Effective. The Restated Certificate shall have been duly adopted by the Company by all necessary corporate action of the Company’s Board of Directors and stockholders, if any, and shall have been duly
filed with and accepted by the Secretary of State of the State of Delaware. 
  
 (f) Compliance Certificate. At the Closing, the Company shall deliver to Cryogen a certificate, dated the date of Closing, signed by the Company’s Chief Executive Officer certifying that the conditions
specified in Sections 7.1(a) and (b) have been fulfilled. 
  
 (g) Securities Laws. The offer and sale of the Shares to Cryogen at the Closing shall be exempt from the registration requirements of the Act and the registration or qualification requirements of all applicable
state securities laws. 
  

 10. 

 (h) License Agreement. The Company shall have executed and delivered to Cryogen the License
Agreement. 
  
 (i) Development Agreement. The Company
shall have executed and delivered to Cryogen the Development Agreement. 
  
 (j) Series B Financing. The Company shall have completed the Series B Financing on terms and conditions satisfactory to Cryogen. 
  
 (k) Waivers and Consents. Cryogen shall have received consents and waivers from each of Comdisco, Inc. and Lease
Management Services, Inc. with respect to the transactions contemplated hereby and by the Related Agreements. 
  
 8. CONDITIONS TO COMPANY’S OBLIGATIONS AT THE CLOSING. 
  
 8.1 Conditions to Closing. The obligation of the Company to issue Shares at the Closing is subject to the
fulfillment, to the satisfaction of the Company on or prior to the Closing, of the following conditions: 
  
 (a) Representations and Warranties. The representations and warranties of Cryogen contained in Section 4 shall be true and correct when
made, and shall be true and correct as of the date of the Closing with the same force and effect as if they had been made on and as of such date. 
  
 (b) Restated Certificate of Incorporation Effective. The Restated Certificate shall have been duly adopted by the Company by all necessary
corporate action of the Company Board of Directors and stockholders, if any, and shall have been duly filed with and accepted by the Secretary of State of the State of Delaware. 
  
 (c) Securities Exemptions. The offer and sale of the Shares to Cryogen pursuant to this Agreement shall be exempt
from the registration requirements of the Act and the registration or qualification requirements of all applicable state securities laws. 
  
 (d) Assignment and Assumption Documents. Cryogen shall have executed and delivered to the Company the Assignment and Assumption Documents

  
 (e) License Agreement. Cryogen shall have executed and
delivered to the Company the License Agreement. 
  
 (f)
Development Agreement. Cryogen shall have executed and delivered to the Company the Development Agreement. 
  
 (g) Waivers and Consents. Cryogen shall have received consents and waivers from each of Comdisco, Inc. and Lease Management Services, Inc. with
respect to the transactions contemplated hereby and by the Related Agreements. 
  

 11. 

 9. DISCLAIMERS; LIMITATIONS. 
  
 9.1 NO WARRANTY. EXCEPT AS EXPRESSLY PROVIDED BY CRYOGEN IN SECTION 4, ALL LICENSED TECHNOLOGY SHALL BE
PROVIDED “AS IS,” WITHOUT ANY WARRANTY OF ANY KIND AND CRYOGEN MAKES NO WARRANTIES WITH RESPECT TO THE LICENSED TECHNOLOGY, EITHER EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, NONINFRINGEMENT, FITNESS FOR
A PARTICULAR PURPOSE OR VALIDITY OR ENFORCEABILITY OF ANY PATENTS ISSUED OR APPLIED FOR IN CONNECTION WITH THE LICENSED TECHNOLOGY. 
  
 9.2 No Consequential Damages. Liability arising under this Agreement, under any cause of action or theory of liability, other than liability
arising as a result of a party’s obligations under Section 6.2 hereof, shall be limited to direct, objectively measurable damages. EXCEPT AS A RESULT OF THE BREACH OF A PARTY’S OBLIGATIONS SET FORTH IN SECTION 6.2 HEREOF, NO
PARTY SHALL HAVE ANY LIABILITY TO ANY OTHER PARTY OR ANY THIRD PARTY FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL OR SPECULATIVE DAMAGES, INCLUDING, WITHOUT LIMITING THE FOREGOING, LOST PROFITS, LOST DATA, LOSS OF OPPORTUNITY, LOSS OF USE OR COSTS OF
PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, BUSINESS INTERRUPTIONS, AND LOSS OF PROFITS, IRRESPECTIVE OF WHETHER THE PARTY HAS ADVANCE NOTICE OF THE POSSIBILITY OF ANY SUCH DAMAGES. These limitations shall apply notwithstanding the failure of the
essential purpose of any limited remedy. 
  
 10. MISCELLANEOUS.

  
 10.1 Survival. The representations, warranties,
covenants and agreements made herein shall survive any investigation made by any party hereto and the closing of the transactions contemplated hereby. 
  
 10.2 Successors and Assigns. Except as otherwise expressly provided in this Agreement, the provisions of this Agreement shall inure to the benefit
of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties to this Agreement whose rights or obligations hereunder are affected by such amendments. This Agreement and the rights and obligations in it may not
be assigned by any party hereto without the written consent of the other parties hereto. 
  
 10.3 Entire Agreement. This Agreement, together with the Related Agreements, and the schedules and exhibits to this Agreement and the Related Agreements which are hereby expressly incorporated in this Agreement
constitute the entire understanding and agreement between the parties with regard to the subjects hereof and thereof. 
  
 10.4 Notices. Except as may be otherwise provided herein, all notices, requests, waivers and other communications made pursuant to this Agreement
shall be in writing and shall be conclusively deemed to have been duly given: (a) when hand delivered to the other party; (b) when received when sent by facsimile at the address set forth below; (c) three (3) business days after deposit in the U.S.
mail with first class or certified mail receipt requested 

  

 12. 

 
postage prepaid and addressed to the other party as set forth below; or (d) the next business day after deposit with a national overnight delivery service,
postage prepaid, addressed to the parties as set forth below with next-business-day delivery guaranteed, provided that the sending party receives a confirmation of delivery from the delivery service provider. 
  
 To the Company: 
  
 c/o MPM Asset Management LLC 
 601 Gateway Blvd., Suite 300 
 South San Francisco, CA 94080 
 Facsimile: (650) 829-5828 
 Attention: Gregory
M. Ayers, M.D., Ph.D. 
  
 With copies to: 
  
 Gray Cary Ware & Freidenrich LLP 
 4365 Executive Drive, Suite 1600 
 San Diego,
California 92121 
 Facsimile: (858) 677-1477 
 Attention: Paul E. Kreutz, Esq. 
  
 To Cryogen:

  
 Cryogen, Inc. 
 11065 Sorrento Valley Court 
 San Diego,
California 92121 
 Facsimile: (858) 450-3187 
 Attention: President 
  
 With copies to:

  
 Brobeck, Phleger & Harrison LLP 
 12390 El Camino Real 
 San Diego, California
92130 
 Facsimile: (858) 720-2555 
 Attention: Michael S. Kagnoff, Esq. 
  
 Each person making a
communication hereunder by facsimile shall promptly confirm by telephone to the person to whom such communication was addressed each communication made by it by facsimile pursuant hereto but the absence of such confirmation shall not affect the
validity of any such communication. A party may change or supplement the addresses given above, or designate additional addresses, for purposes of this Section 10.4 by giving the other party written notice of the new address in the manner set
forth above. 
  
 10.5 Amendments and Waivers. Any term of
this Agreement may be amended only with the written consent of Cryogen and the Company. 
  

 13. 

 10.6 Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to
the Company or to Cryogen, upon any breach or default of any party hereto under this Agreement, shall impair any such right, power or remedy of the Company, or Cryogen nor shall it be construed to be a waiver of any such breach or default, or an
acquiescence therein, or of any similar breach of default thereafter occurring; nor shall any waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of
the Company or Cryogen of any breach of default under this Agreement or any waiver on the part of the Company or Cryogen of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set
forth in such writing. All remedies, either under this Agreement, or by law or otherwise afforded to the Company or Cryogen shall be cumulative and not alternative. 
  
 10.7 Legal Fees. In the event of any action at law, suit in equity or arbitration proceeding in relation to this
Agreement, the prevailing party, shall be paid by the non-prevailing party a reasonable sum for attorneys’ fees and expenses for such prevailing party. 
  
 10.8 Finder’s Fees. Each party represents and warrants to the other parties to the Agreement that it has retained no finder or broker in
connection with the transactions contemplated by this Agreement. 
  
 10.9 Titles and Subtitles. The titles of the sections, paragraphs and subparagraphs of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement. 
  
 10.10 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be an original, but all of which together shall constitute one instrument. 
  
 10.11 Severability. Should any provision of this Agreement be determined to be illegal or unenforceable, such determination shall not affect the
remaining provisions of this Agreement. 
  
 10.12 Governing
Law; Consent to Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of the State of California without regard to conflicts of law principles. Any action or proceeding, however characterized, relating to or
arising out of this Agreement, or in connection with the subject matter hereof shall be maintained in the state or federal courts located in San Diego County, California, and the parties hereto, each for itself, its successors and permitted assigns,
hereby irrevocably submits to the jurisdiction of the courts of the State of California and the Courts of the United States of America sitting in the San Diego County, California for the purposes of any such action or proceeding and irrevocably
agrees to be bound by any judgment rendered thereby in connection with this Agreement. 
  
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

 13. 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year herein above
first written. 
  

			
	“COMPANY”
	
	CRYOCOR, INC.
		
	 By:
	 	 /s/    Gregory M. Ayers

	 Name:
	 	 Gregory M. Ayers

	 Title:
	 	 President & CEO

	
	“CRYOGEN”
	
	CRYOGEN, INC.
		
	 By:
	 	 /s/    David R. Murray

	 Name:
	 	 David R. Murray

	 Title:
	 	 President & CEO

 SCHEDULE 3.3 
  
 CAPITALIZATION 
  
 The Company is entering into an employment agreement with Gregory Ayers which provides for the issuance of an option to purchase up to 700,000 shares of
the Company’s common stock under the Company’s 2000 Stock Option Plan. 
  
 Additionally, the Company plans to extend offer letters to certain potential employees which involve the future issuance of up to 215,000 shares of the Company’s common stock under the Company’s 2000 Stock
Option Plan. 

 SCHEDULE 4.4 
  
 LITIGATION 
  
 [...***...] 
  
 * Confidential Treatment Requested 

 SCHEDULE 4.5 
  
 INTELLECTUAL PROPERTY 
  
 Cryogen is a party to an Exclusive License Agreement with National Institute for Standards and Technology (“NIST”) effective January 27, 1997
(the “NIST License”), a copy of which has been provided to the Company and its counsel. Each of NIST and Cryogen owns an undivided interest in the patent applications and associated patent rights covered by the NIST License and marked with
an asterisk (*) on Exhibit A to the License Agreement. 

 SCHEDULE 6.3 
  
 CRYOCOR EMPLOYEES 
  
 [...***...] 
  
 * Confidential Treatment Requested 

 EXHIBIT A 
  
 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION 

 EXHIBIT B 
  
 LISTING OF ASSETS TRANSFERRED 
  

					
	 Asset Description

	 	 Asset Number

	 	 Asset Source

	 [...***...]
	 	[...***...]	 	[...***...]
	 [...***...]
	 	[...***...]	 	[...***...]
	 [...***...]
	 	[...***...]	 	[...***...]
	 [...***...]
	 	[...***...]	 	[...***...]
	 [...***...]
	 	[...***...]	 	[...***...]
	 [...***...]
	 	[...***...]	 	[...***...]
	 [...***...]
	 	[...***...]	 	[...***...]
	 [...***...]
	 	[...***...]	 	[...***...]
	 [...***...]
	 	[...***...]	 	[...***...]
	 [...***...]
	 	[...***...]	 	[...***...]
	 [...***...]
	 	[...***...]	 	[...***...]
	 [...***...]
	 	[...***...]	 	[...***...]

  
 * Confidential
Treatment Requested 
  
  

 EXHIBIT C 
  
 LICENSE AGREEMENT 

 EXHIBIT D 
  
 DEVELOPMENT AGREEMENT 

 EXHIBIT E 
  
 CONTRIBUTED CLINICAL DEVELOPMENT PRODUCTS 
  
 [...***...] 
  
 * Confidential Treatment Requested 

 EXHIBIT F 
  
 PURCHASED MOLDS CONTRACTS 
  
 Contracts, agreements and purchase orders for the production of Purchased Molds, with an outstanding aggregate balance to be paid to such vendors of
$[...***...], between Cryogen and each of the following vendors: 
  
 [...***...] 
  
 * Confidential Treatment RequestedLicense Agreement

 Exhibit 10.13 
  
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested 
 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 230.406 
  
 LICENSE AGREEMENT 
  
 This License Agreement (“Agreement”) is entered into effective as of this 31st day of August, 2000 (“Effective Date”), by and between Cryogen, Inc., a California corporation
(“Cryogen”), and CryoCor, Inc., a Delaware corporation (“CryoCor”). 
  
 WITNESSETH 
  
 WHEREAS, Cryogen is willing to grant a license to CryoCor with respect to certain of its intellectual property rights and CryoCor is willing to grant licenses to Cryogen with respect to certain enhancements thereof; 
  
 WHEREAS, it is a condition to the closing of the transactions contemplated by
that certain Contribution Agreement of even date herewith between the parties hereto (the “Contribution Agreement”) that the parties hereto enter into this Agreement. 
  
 NOW THEREFORE 
  
 In view of the foregoing premises and the mutual covenants set forth herein and for other good and valuable consideration, the receipt and sufficiency of
this is hereby acknowledged, the parties hereto hereby agree as follows: 
  
 1. DEFINITIONS 
  
 1.1
“Affiliate” means a corporation, company, or other legal entity now or hereinafter controlling, controlled by or under common control with a party hereto, for so long as such ownership or control exists. For the purposes of this
definition, control shall refer to a greater than 50% interest in the right to make decisions for such entity (e.g., greater than 50% ownership of the voting shares or other voting securities of such entity). Notwithstanding anything to the contrary
contained herein, “Affiliate” shall not include (i) in the case of Cryogen, CryoCor and (ii) in the case of CryoCor, Cryogen. 
  
 1.2 “Assigned Assets and Clinical Development Products” shall mean the assets and clinical development products assigned to CryoCor by
Cryogen pursuant to Section 1.2(a)(i) of the Contribution Agreement. 
  
 1.3 “CryoCor Enhancements” means any and all modifications, improvements and enhancements to the Cryogen Intellectual Property Rights, Licensed Products and Assigned Assets and Clinical Development Products made or
developed by or on behalf of CryoCor that may be used or useful in the Cryogen Fields and which have been reduced to a form of Written Idea Memorandum on or before [...***...]; provided, however, “CryoCor Enhancements” shall not
include such modifications, improvements and enhancements to the Cryogen Intellectual Property Rights, made or developed solely by Cryogen (or its employees) on behalf of CryoCor pursuant to the R&D Agreement. 
  
 1.4 “CryoCor Field” means cardiac or vascular
ablation to treat cardiac arrhythmias. 
  

					
	 	 	1.	 	* Confidential Treatment Requested

 1.5 “CryoCor Joint Enhancement Interest” means CryoCor’s undivided ownership
interest in a Joint Enhancement. 
  
 1.6 “Cryogen
Enhancements” means any and all modifications, improvements and enhancements to the Cryogen Intellectual Property Rights or to Licensed Products made or developed by or on behalf of Cryogen that may be used or useful in the CryoCor Field or
in connection with any of the Licensed Products and which have been reduced to a form of Written Idea Memorandum on or before [...***...]. Without limiting the generality of the foregoing, “Cryogen Enhancements” shall include such
modifications, improvements and enhancements to the Cryogen Intellectual Property Rights made or developed solely by Cryogen (or its employees) on behalf of CryoCor pursuant to the R&D Agreement. 
  
 1.7 “Cryogen Exclusive Field” means [...***...].

  
 1.8 “Cryogen Fields” means the Cryogen
Exclusive Field and the Cryogen Nonexclusive Field. 
  
 1.9
“Cryogen Intellectual Property Rights” means the intellectual property rights owned by Cryogen used or useful in the CryoCor Field, as particularly set forth and described in Exhibit A hereto. 
  
 1.10 “Cryogen Joint Enhancement Interest” means
Cryogen’s undivided ownership interest in a Joint Enhancement. 
  
 1.11 “Cryogen Nonexclusive Field” means any and all fields of use other than the CryoCor Field and the Cryogen Exclusive Field. 
  
 1.12 “Damages” shall have the meaning set forth in Section 7.2(a) hereof. 
  
 1.13 “Joint Enhancements” means any and all modifications,
improvements and enhancements to the Cryogen Intellectual Property Rights, the Licensed Products or the Assigned Assets and Clinical Development Products, jointly made or jointly developed by Cryogen and CryoCor that may be used or useful in the
CryoCor Field, the Cryogen Fields or in connection with any of the Licensed Products and which have been reduced to a form of Written Idea Memorandum on or before [...***...]. 
  
 1.14 “Licensed Products” means any and all devices and methods conceived, developed, manufactured,
distributed or sold by CryoCor which utilize all or any portion of the Cryogen Intellectual Property Rights, Cryogen Enhancements or Joint Enhancements for use in performing cardiac or vascular ablation to treat cardiac arrhythmias. 
  
 1.15 “NIST” means the National Institute of Standards and
Technology. 
  
 1.16 “NIST License Agreement”
means that certain Exclusive License Agreement effective as of June 27, 1997 between NIST and Cryogen. 
  

					
	 	 	2.	 	* Confidential Treatment Requested

 1.17 “Other Enhancements” means any and all modifications, improvements and enhancements
to the Cryogen Intellectual Property Rights and/or the Licensed Products which are not CryoCor Enhancements, Cryogen Enhancements or Joint Enhancements. 
  
 1.18 “R&D Agreement” means the Research and Development Agreement of even date herewith between Cryogen and CryoCor. 
  
 1.19 “Written Idea Memorandum” means a written memorandum
prepared by Cryogen, CryoCor or jointly by Cryogen and CryoCor, as the case may be, which sets forth in reasonable detail a description of and the planned and potential uses with respect to a Cryogen Enhancement, CryoCor Enhancement or Joint
Enhancement, as the case may be. 
  
 2. LICENSE GRANTS 
  
 2.1 Exclusive License Grant to CryoCor. Cryogen hereby grants to
CryoCor and its Affiliates an exclusive, irrevocable, perpetual, worldwide, non-transferable (except in accordance with Section 8.2 hereof), royalty-free, fully-paid up license, with the right to sublicense, to make, have made, import, use,
have used, offer to sell, sell or have sold Licensed Products and perform and have performed processes under the Cryogen Intellectual Property Rights, the Cryogen Enhancements and the Cryogen Joint Enhancement Interest, solely in the CryoCor Field.

  
 2.2 Non-Exclusive License Grant to Cryogen. CryoCor
hereby grants to Cryogen and its Affiliates a nonexclusive, irrevocable, perpetual, worldwide, non-transferable (except in accordance with Section 8.2 hereof), royalty-free, fully-paid up license, with the right to sublicense, to make, have
made, import, use, have used, offer to sell, sell or have sold products (other than Licensed Products) and perform and have performed processes under the CryoCor Enhancements and the CryoCor Joint Enhancement Interest, solely in the Cryogen
Nonexclusive Field. 
  
 2.3 Exclusive License Grant to
Cryogen. CryoCor hereby grants to Cryogen and its Affiliates an exclusive, irrevocable, perpetual, worldwide, non-transferable (except in accordance with Section 8.2 hereof), royalty-free, fully-paid up license, with the right to
sublicense, to make, have made, import, use, have used, offer to sell, sell or have sold products (other than Licensed Products) and perform and have performed processes under the CryoCor Enhancements and the CryoCor Joint Enhancement interest,
solely in the Cryogen Exclusive Field. 
  
 2.4 Other
Enhancements. Any and all Other Enhancements shall be the sole and exclusive property of the party hereto that makes or discovers any such Other Enhancement and any such Other Enhancement shall not be subject to the licenses granted hereunder by
either Cryogen (pursuant to Section 2.1 hereof) or CryoCor (pursuant to Sections 2.2 or 2.3 hereof). 
  
 2.5 Sublicense of NIST License Agreement. Promptly after CryoCor’s written request, which request shall be received by Cryogen within ninety
(90) days after the date hereof, if at all, Cryogen shall request approval of NIST for an exclusive sublicense to CryoCor for the CryoCor Field of Cryogen’s rights under the NIST License. Cryogen and CryoCor agree that any such sublicense to
CryoCor shall be on substantially the same terms as the license granted 
  

 3. 

 under the NIST License Agreement to Cryogen by NIST as then in effect and such other terms as Cryogen and CryoCor shall
mutually agree in good faith. Notwithstanding the foregoing, Cryogen and CryoCor agree that the terms of any such sublicense shall provide that each of CryoCor and Cryogen shall be responsible for a [...***...] provided in the NIST License
Agreement. 
  
 3. PROSECUTION, MAINTENANCE AND ENFORCEMENT WITH RESPECT TO
CRYOGEN INTELLECTUAL PROPERTY RIGHTS 
  
 3.1 Prosecution
of Patent Applications. Cryogen agrees to use commercially reasonable efforts to maintain and enforce all issued patents included in the Cryogen Intellectual Property Rights (each a “Covered Cryogen Issued Patent”) and to use
commercially reasonable efforts to prosecute all patent applications included in the Cryogen Intellectual Property Rights or the Cryogen Enhancements (each a “Covered Cryogen Patent Application”), all at the sole cost and expense of
Cryogen. The drafting, filing, and prosecution of any Covered Cryogen Patent Application shall be Cryogen’s responsibility and shall be carried out by it in its reasonable discretion, subject to an obligation on the part of Cryogen to keep
CryoCor reasonably informed of all material developments with respect to the foregoing activities. Without limiting the generality of the foregoing, Cryogen shall provide to CryoCor reasonable opportunity to advise Cryogen in the prosecution, filing
and maintenance of the Covered Cryogen Issued Patents and the Covered Cryogen Patent Applications and Cryogen shall implement CryoCor’s requests if and to the extent that such requests are feasible, reasonable and not in conflict with the
policies and objectives of Cryogen as determined by Cryogen; provided, however, CryoCor shall be solely responsible for any and all fees, costs and expenses incurred by Cryogen with respect to the implementation of any such requests by CryoCor.
Notwithstanding the foregoing, if Cryogen determines that it no longer desires to prosecute a Covered Cryogen Patent Application or maintain a Covered Cryogen Issued Patent, it shall, by giving CryoCor corresponding notice in writing, offer to
CryoCor the assignment of its right, title and interest in such Covered Cryogen Patent Application or Covered Cryogen Issued Patent, as the case may be. If CryoCor accepts such offer within sixty (60) days after Cryogen gives such notice, Cryogen
shall assign to CryoCor all of Cryogen’s right, title and interest in such Covered Cryogen Patent Application or Covered Cryogen Issued Patent (subject to an irrevocable, perpetual, royalty-free, exclusive, unrestricted, sublicensable,
worldwide license in favor of Cryogen for applications other than Licensed Products), at no charge to CryoCor. Following any such assignment, CryoCor may draft, file, maintain, prosecute and defend such assigned Covered Cryogen Patent Application or
Covered Cryogen Issued Patent, as the case may be, in it sole discretion. Pending receipt of a response from CryoCor as to whether CryoCor will accept such offer or, if later, the expiration of sixty (60) day period, Cryogen shall use reasonable
efforts to extend any deadlines or take such action as may be reasonably required to prevent the abandonment of any such Covered Cryogen Patent Application or forfeiture of any such Covered Cryogen Issued Patent. 
  
 3.2 Infringement by Third Parties. 
  
 (a) CryoCor will promptly notify Cryogen in writing of any apparent
infringement, misappropriation or other wrongful exploitation of the Cryogen Intellectual Property Rights or Cryogen Enhancements by a third party, including, without limitation, infringement, misappropriation or other wrongful exploitation in the
field of using, making, selling, importing or otherwise commercially exploiting Licensed Products in the CryoCor Field. 
  

					
	 	 	4.	 	* Confidential Treatment Requested

 (i) Cryogen shall have the initial right, at its sole cost and expense, to determine whether to
bring suit to enjoin such infringement, misappropriation or wrongful exploitation and recover damages therefor. Cryogen will bring such action in its name, at its sole cost and expense, and will take such other action, at its sole cost and expense
in connection with the prosecution of such action. Any damages recovered in such action will be payable to Cryogen for its exclusive benefit. 
  
 (ii) If Cryogen does not bring any such action as provided in Section 3.2(a)(i) above, within [...***...] after written notice of
infringement, misappropriation or wrongful exploitation is given by CryoCor, CryoCor may cause Cryogen, at CryoCor’s sole cost and expense to bring suit in Cryogen’s name or Cryogen’s and CryoCor’s names to enjoin such
infringement, misappropriation or wrongful exploitation and recover damages therefor (the “Total Damages”), which shall be for CryoCor’s sole account to the extent the damages are attributable to use and exploitation of the
Cryogen Intellectual Property Rights or Cryogen Enhancements within the CryoCor Field (the “CryoCor Damages”) and shall be for the account of Cryogen to the extent the damages are attributable to use and exploitation of the Cryogen
Intellectual Property Rights or Cryogen Enhancements outside of the CryoCor Field (the “Cryogen Damages”) upon Cryogen’s reimbursement to CryoCor of Cryogen’s proportionate share of the costs and expenses of such action
equal to the Cryogen Damages divided by the Total Damages. 
  
 (b) In any action brought by Cryogen pursuant to either Section 3.2(a)(i) or Section 3.2(a)(ii) hereof, Cryogen shall select and control counsel for the prosecution of such suit. Cryogen agrees to keep CryoCor
reasonably informed of any and all material developments with respect to any such action or suit, all at the sole cost and expense of CryoCor, and shall give CryoCor the opportunity to review in advance all major decisions, positions or actions that
Cryogen wishes to take in any such action or suit which would impair any interest of CryoCor in the Cryogen Intellectual Property Rights, Cryogen Enhancements or the Licensed Products. Without limiting the generality of the foregoing, CryoCor shall
(i) have the right to receive, from time to time, full and complete information from Cryogen concerning the status of such suit, (ii) have the right, at its sole cost and expense, to be represented therein by separate counsel in advisory or
consultative capacity, and (iii) cooperate fully with Cryogen and provide whatever assistance is reasonably requested by Cryogen in connection with such suit, including the preparation and signing of documents. Cryogen shall have the right to settle
any infringement suit described in either Section 3.2(a)(i) or Section 3.2(a)(ii) hereof in its sole discretion, after reasonable prior consultation with CryoCor and good faith consideration of CryoCor’s requests and proposals.

  
 4. PROSECUTION MAINTENANCE AND ENFORCEMENT WITH RESPECT TO ENHANCEMENTS

  
 4.1 Prosecution of CryoCor Enhancement Patent
Applications. CryoCor agrees to use commercially reasonable efforts to maintain and enforce all issued patents included in the CryoCor Enhancements (each a “Covered Enhancement Issued Patent”) and to use commercially 

 

					
	 	 	5.	 	* Confidential Treatment Requested

 reasonable efforts to prosecute all patent applications included in the CryoCor Enhancements (each a “Covered
Enhancement Patent Application”), all at the sole cost and expense of CryoCor. The drafting, filing, and prosecution of any Covered Enhancement Patent Application shall be CryoCor’s responsibility and shall be carried out by it in its
reasonable discretion, subject to an obligation on the part of CryoCor to keep Cryogen reasonably informed of all material developments with respect to the foregoing activities. Without limiting the generality of the foregoing, CryoCor shall provide
to Cryogen reasonable opportunity to advise CryoCor in the prosecution, filing and maintenance of the Covered Enhancement Issued Patents and the Covered Enhancement Patent Applications and CryoCor shall implement Cryogen’s requests if and to
the extent that such requests are feasible, reasonable and not in conflict with the policies and objectives of CryoCor as determined by CryoCor; provided, however, Cryogen shall be solely responsible for any and all fees, costs and expenses incurred
by CryoCor with respect to the implementation of any such requests by Cryogen. Notwithstanding the foregoing, if CryoCor determines that it no longer desires to prosecute a Covered Enhancement Patent Application or maintain a Covered Enhancement
Issued Patent, it shall, by giving Cryogen corresponding notice in writing, offer to Cryogen the assignment of its right, title and interest in such Covered Enhancement Patent Application or Covered Enhancement Issued Patent, as the case may be. If
Cryogen accepts such offer within sixty (60) days after CryoCor gives such notice, CryoCor shall assign to Cryogen all of CryoCor’s right, title and interest in such Covered Enhancement Patent Application or Covered Enhancement Issued Patent
(subject to an irrevocable, perpetual, royalty-free, exclusive, unrestricted, sublicensable, worldwide license in favor of CryoCor for applications for Licensed Products), at no charge to Cryogen. Following any such assignment, CryoCor may draft,
file, maintain, prosecute and defend such assigned Covered Enhancement Patent Application or Covered Enhancement Issued Patent, as the case may be, in it sole discretion. Pending receipt of a response from Cryogen as to whether Cryogen will accept
such offer or, if later, the expiration of sixty (60) day period, CryoCor shall use reasonable efforts to extend any deadlines or take such action as may be reasonably required to prevent the abandonment of any such Covered Enhancement Patent
Application or forfeiture of any such Covered Enhancement Issued Patent. 
  
 4.2 Infringement of CryoCor Enhancements by Third Parties. 
  
 (a) Cryogen will promptly notify CryoCor in writing of any apparent infringement, misappropriation or other wrongful exploitation of the CryoCor
Enhancements by a third party. 
  
 (i) CryoCor shall have
the initial right, at its sole cost and expense, to determine whether to bring suit to enjoin such infringement, misappropriation or wrongful exploitation and recover damages therefor. CryoCor will bring such action in its name, at its sole cost and
expense, and will take such other action, at its sole cost and expense in connection with the prosecution of such action. Any damages recovered in such action will be payable to CryoCor for its exclusive benefit. 
  
 (ii) If CryoCor does not bring any such action as provided in
Section 4.2(a)(i) above, within [...***...] after written notice of infringement, misappropriation or wrongful exploitation is given by Cryogen, Cryogen may cause CryoCor, at Cryogen’s sole cost and expense to bring suit in
CryoCor’s name or Cryogen’s and CryoCor’s names to enjoin such 
  

					
	 	 	6.	 	* Confidential Treatment Requested

 infringement, misappropriation or wrongful exploitation and recover damages therefor (the “Total Enhancement
Damages”), which shall be for Cryogen’s sole account to the extent the damages are attributable to use and exploitation of the CryoCor Enhancements within the Cryogen Fields (the “Cryogen Enhancement Damages”) and
shall be for the account of CryoCor to the extent the damages are attributable to use and exploitation of the CryoCor Enhancements within the CryoCor Field (the “CryoCor Enhancement Damages”) upon CryoCor’s reimbursement to
Cryogen of CryoCor’s proportionate share of the costs and expenses of such action equal to the CryoCor Enhancement Damages divided by the Total Enhancement Damages. 
  
 (b) In any action brought by CryoCor pursuant to either Section 4.2(a)(i) or Section 4.2(a)(ii) hereof,
CryoCor shall select and control counsel for the prosecution of such suit. CryoCor agrees to keep Cryogen reasonably informed of any and all material developments with respect to any such action or suit, all at the sole cost and expense of Cryogen,
and shall give Cryogen the opportunity to review in advance all major decisions, positions or actions that CryoCor wishes to take in any such action or suit which would impair any interest of Cryogen in the CryoCor Enhancements. Without limiting the
generality of the foregoing, Cryogen shall (i) have the right to receive, from time to time, full and complete information from CryoCor concerning the status of such suit, (ii) have the right, at its sole cost and expense, to be represented therein
by separate counsel in advisory or consultative capacity, and (iii) cooperate fully with CryoCor and provide whatever assistance is reasonably requested by CryoCor in connection with such suit, including the preparation and signing of documents.
CryoCor shall have the right to settle any infringement suit described in either Section 4.2(a)(i) or Section 4.2(a)(ii) hereof in its sole discretion, after reasonable prior consultation with Cryogen and good faith consideration of
Cryogen’s requests and proposals. 
  
 4.3 Prosecution of
Joint Enhancement Patent Applications. Each of Cryogen and CryoCor agrees to use commercially reasonable efforts to jointly maintain and jointly enforce all issued patents included in the Joint Enhancements (each a “Covered Joint
Enhancement Issued Patent”) and to use commercially reasonable efforts to prosecute all patent applications included in the Joint Enhancements (each a “Covered Joint Enhancement Patent Application”), the costs and expenses
of which shall be borne equally by Cryogen and CryoCor. The drafting, filing, and prosecution of any Covered Joint Enhancement Patent Application shall be the shared responsibility of Cryogen and CryoCor and shall be carried out by them in good
faith and with joint cooperation, subject to an obligation on the part of each party to keep the other party reasonably informed of all material developments with respect to the foregoing activities. Without limiting the generality of the foregoing,
each party shall provide the other party with reasonable opportunity to provide advice in the prosecution, filing and maintenance of the Covered Joint Enhancement Issued Patents and the Covered Joint Enhancement Patent Applications and the parties
shall implement one another’s requests if and to the extent that such requests are feasible and reasonable. Notwithstanding the foregoing, if either party (a “Tendering Party”) determines that it no longer desires to jointly
prosecute a Covered Joint Enhancement Patent Application or jointly maintain a Covered Joint Enhancement Issued Patent, it shall, by giving the other party corresponding notice in writing, offer to the other party the assignment of its undivided
right, title and interest in such Covered Joint Enhancement Patent Application or Covered Joint Enhancement Issued Patent, as the case may be. If such other party accepts such offer within [...***...] after its receipt of such notice, such
Tendering Party shall 
  

					
	 	 	7.	 	* Confidential Treatment Requested

 assign to such other party all of the Tendering Party’s undivided right, title and interest in such Covered Joint
Enhancement Patent Application or Covered Joint Enhancement Issued Patent (subject to an irrevocable, perpetual, royalty-free, exclusive, unrestricted, sublicensable, worldwide license in favor of the Tendering Party for either applications for
Licensed Products (if such Tendering Party is CryoCor) or applications for other than Licensed Products (if such Tendering Party is Cryogen), as the case may be), at no charge to such other party. Following any such assignment, such other party may
draft, file, maintain, prosecute and defend, or abandon, such assigned Covered Joint Enhancement Patent Application or Covered Joint Enhancement Issued Patent, as the case may be, in its sole discretion. Pending receipt of a response from such other
party as to whether such other party will accept such offer or, if later, the expiration of [...***...] period, the Tendering Party shall use reasonable efforts to assist such other party in extending any deadlines or taking such action as may
be reasonably required to prevent the abandonment of any such Covered Joint Enhancement Patent Application or forfeiture of any such Covered Joint Enhancement Issued Patent. 
  
 4.4 Infringement of Joint Enhancements by Third Parties. Each party will promptly notify the other party in writing
of any apparent infringement, misappropriation or other wrongful exploitation of a Joint Enhancement by a third party. Cryogen and CryoCor shall jointly determine in good faith whether to bring suit to enjoin such infringement, misappropriation or
wrongful exploitation and recover damages therefor. Cryogen and CryoCor will jointly bring such action in their names, the cost and expense of which shall be borne equally by Cryogen and CryoCor. Any damages recovered in such action will be shared
equally by Cryogen and CryoCor. Cryogen and CryoCor shall jointly select and jointly control counsel for the prosecution of such suit and shall settle any such suits only upon joint agreement. Each party agrees to keep the other party reasonably
informed of any and all material developments with respect to any such action or suit, and each party shall be given the opportunity to review in advance all major decisions, positions or actions that either party wishes to take in any such action
or suit. 
  
 5. REPRESENTATIONS, WARRANTIES AND DISCLAIMERS 
  
 5.1 NO WARRANTY. EXCEPT AS EXPRESSLY PROVIDED BY CRYOGEN IN SECTION 4
OF THE CONTRIBUTION AGREEMENT AND IN THIS SECTION 5, ALL CRYOGEN INTELLECTUAL PROPERTY RIGHTS SHALL BE PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND AND CRYOGEN MAKES NO WARRANTIES WITH RESPECT TO THE CRYOGEN INTELLECTUAL
PROPERTY RIGHTS, EITHER EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANT ABILITY NONINFRINGEMENT, FITNESS FOR A PARTICULAR PURPOSE OR THE VALIDITY OR ENFORCEABILITY OF ANY PATENTS ISSUED OR APPLIED FOR IN CONNECTION WITH THE CRYOGEN
INTELLECTUAL PROPERTY RIGHTS. 
  
 5.2 Neither party
warrants or represents or shall be deemed to have represented or warranted that the rights granted hereunder will result in commercially acceptable or marketable product lines. 
  

					
	 	 	8.	 	* Confidential Treatment Requested

 5.3 This Agreement does not confer by implication, estoppel, laches or by any other means any
license or any rights other than those expressly granted herein. 
  
 5.4 Without limiting or restricting the covenants and agreements of CryoCor set forth in Section 7.1 hereto, Cryogen represents and warrants that each of the Contributed Clinical Development Products (as such term is defined
in the Contribution Agreement) has been manufactured in accordance with the existing specifications of Cryogen for such Contributed Clinical Development Products. 
  
 5.5 Each patent and patent application owned by Cryogen and used or useful in the CryoCor Field constitutes a part of
the Cryogen Intellectual Property Rights as set forth and described on Exhibit A hereto. The representations and warranties of Cryogen contained in Section 4.5 of the Contribution Agreement are incorporated herein by reference. 
  
 6. CONFIDENTIALITY 
  
 6.1 Any and all files and records pertaining to the Cryogen Intellectual Property Rights previously or hereafter
provided by Cryogen to CryoCor or any of its officers, directors, employees, consultants, stockholders or representative shall be treated as “Confidential Information” of Cryogen by CryoCor. 
  
 6.2 Confidentiality Obligations. 
  
 (a) Any party to this Agreement (the “Disclosing
Party”) may from time to time disclose Confidential Information to the other party to this Agreement (each a “Recipient”). “Confidential Information” is all nonpublic information concerning the unpatented
intellectual property (and any and all rights therein or applications thereof), product specifications, any and all know-how, methods and processes with respect to products and marketing plans and marketing strategies and general market data of the
Disclosing Party which is conveyed to the Recipient orally or in tangible form. Recipient shall keep in confidence and trust and shall not disclose or disseminate, or permit any employee, agent or other person working under Recipient’s
direction to disclose or disseminate, the existence, source, content or substance of any Confidential Information to any other person or entity. Recipient shall use Confidential Information of the Disclosing Party only as necessary for the
performance of this Agreement, the Contribution Agreement of even date herewith between the parties hereto (the “Contribution Agreement”) and the Development Agreement of even date herewith between the parties hereto (together with
the Contribution Agreement, the “Related Agreements”); provided, however, a Recipient may disclose Confidential Information to one or more potential financing sources upon the prior written consent of the Disclosing Party which
consent shall not be unreasonably withheld or delayed. Recipient shall employ at least the same methods and degree of care, but no less than a reasonable degree of care, to prevent disclosure of the Confidential Information as Recipient employs with
respect to its own confidential trade secrets and proprietary information. Recipient’s employees and independent contractors shall be given access to the Confidential Information only on a need-to-know basis, and only if they have executed a
form of nondisclosure agreement with Recipient which imposes a duty to maintain the confidentiality of the Confidential Information that is at least as restrictive as the terms of this Section 6.2. 
  

 9. 

 (b) The commitments in this Section 6.2 shall not impose any obligations on Recipient with
respect to any portion of the received information which: (i) is now generally known by or available to the public or which hereafter, through no act or failure to act on the part of Recipient, becomes generally known or available in the public
domain; (ii) is furnished to Recipient by a third party without restriction on disclosure and without a breach by such third party of any confidentiality undertaking with respect thereto; or (iii) is required to be disclosed by operation of law or
by an instrumentality of the government, including but not limited to any court, tribunal or administrative agency; provided that, in the case of any disclosure required by court order, the Recipient shall give the Disclosing Party as much advance
notice as is reasonably practicable under the circumstances so as to permit the Disclosing Party to seek a protective order. 
  
 (c) The terms of Section 6.2 of the Contribution Agreement shall control in the event of a conflict between this Section 6.2 and the
confidentiality and non-disclosure agreements contained in the Related Agreements (or any of them). 
  
 (d) The obligations of the parties hereto under this Section 6.2 shall survive indefinitely. 
  
 7. PRODUCT LIABILITY AND INDEMNIFICATION 
  
 7.1 Product Defects. With respect to Licensed Products conceived,
developed, manufactured or sold after the Effective Date, CryoCor will have full responsibility for determining that the designs of the Licensed Products and components made by or for CryoCor are manufactured in accordance with customary commercial
standards. 
  
 7.2 Indemnity. 
  
 (a) CryoCor hereby agrees to indemnify and hold harmless Cryogen and
its Affiliates and their respective officers, directors, employees, consultants and shareholders from and against any and all claims, demands, and actions, and any liabilities, damages, or expenses resulting therefrom, including court costs and
reasonable attorneys’ fees and expenses (collectively “Damages”), resulting from the conception, development, manufacture, sale, offer to sell, distribution, importation or use of the Cryogen Intellectual Property Rights, the
Cryogen Enhancements or the Joint Enhancements by CryoCor or its Affiliates, including, without limitation, any Damages based upon or relating to Licensed Products or any other products or services provided or offered by CryoCor. CryoCor’s
obligations under this Section 7.2(a) shall survive the termination of this Agreement for any reason. Cryogen agrees to give CryoCor prompt notice of any such claim, demand, or action and to cooperate in the defense and settlement of said
claim, demand, or action as reasonably requested by CryoCor, provided, that CryoCor shall reimburse Cryogen for all reasonable expenses incurred as a result of such cooperation. 
  
 (b) Cryogen hereby agrees to indemnify and hold harmless CryoCor and its Affiliates and their respective officers,
directors, employees, consultants and shareholders from and against any and all Damages, resulting from the conception, development, manufacture, sale, offer to sell, distribution, importation or use of the CryoCor Enhancements or the Joint

  

 10. 

 Enhancements by Cryogen or its Affiliates, including, without limitation, any Damages based upon or relating to products
or services provided or offered by Cryogen. Cryogen’s obligations under this Section 7.2(b) shall survive the termination of this Agreement for any reason. CryoCor agrees to give Cryogen prompt notice of any such claim, demand, or action
and to cooperate in the defense and settlement of said claim, demand, or action as reasonably requested by Cryogen, provided, that Cryogen shall reimburse CryoCor for all reasonable expenses incurred as a result of such cooperation. 
  
 7.3 Insurance. 
  
 (a) CryoCor shall maintain at all times during the period that any
Licensed Products are being distributed or sold by CryoCor hereunder, and thereafter for the time any such Licensed Products remain in clinical use, comprehensive general liability insurance, with endorsements for contractual liability and product
liability with coverage limits of not less than [...***...]. Cryogen shall, under such insurance, be named as an additional insured with a cross-liability endorsement. The minimum level of insurance set forth herein shall not be construed to
create a limit on CryoCor’s liability with respect to its indemnification obligations hereunder. Prior to the commencement of clinical use (including commencement of human clinical trials) of Licensed Products, and on each subsequent
anniversary of the Effective Date, CryoCor shall furnish to Cryogen a certificate of insurance evidencing such coverage as of the date of commencement of such clinical use (and each anniversary thereof) and upon request by Cryogen at any time
hereafter. Each such certificate of insurance shall include a provision whereby sixty (60) days written notice must be received by Cryogen prior to coverage modification or cancellation by either CryoCor or the insurer. 
  
 (b) Cryogen shall maintain at all times during the period that any
products utilizing any of the CryoCor Enhancements or the Joint Enhancements are being distributed or sold by Cryogen hereunder, and thereafter for the time any such products remain in clinical use, comprehensive general liability insurance, with
endorsements for contractual liability and product liability with coverage limits of not less than [...***...]. CryoCor shall, under such insurance, be named as an additional insured with a cross-liability endorsement. The minimum level of
insurance set forth herein shall not be construed to create a limit on Cryogen’s liability with respect to its indemnification obligations hereunder. Prior to the commencement of clinical use (including commencement of human clinical trials) of
products utilizing CryoCor Enhancements, Cryogen shall furnish to CryoCor a certificate of insurance evidencing such coverage as of the date of commencement of such clinical use (and each anniversary thereof) and upon request by CryoCor at any time
hereafter. Each such certificate of insurance shall include a provision whereby sixty (60) days written notice must be received by CryoCor prior to coverage modification or cancellation by either Cryogen or the insurer. 
  
 8. GENERAL PROVISIONS 
  
 8.1 Governing Law; Consent to Jurisdiction. This Agreement shall be governed by and construed in accordance with the
laws of the State of California without regard to conflicts of law principles. Any action or proceeding, however characterized, relating to or arising out of this Agreement, or in connection with the subject matter hereof shall be maintained in the
state or federal courts located in San Diego County, California, and the parties hereto, each for itself, 
  

					
	 	 	11.	 	* Confidential Treatment Requested

 its successors and permitted assigns, hereby irrevocably submits to the jurisdiction of the courts of the State of
California and the Courts of the United States of America sitting in the San Diego County, California for the purposes of any such action or proceeding and irrevocably agrees to be bound by any judgment rendered thereby in connection with this
Agreement. 
  
 8.2 Assignment. Neither this Agreement nor
the licenses granted hereunder may be assigned by either party without the prior written consent of the other party, except that upon a merger, or acquisition of all or substantially all of the capital stock or assets of a party, such consent shall
not be required. 
  
 8.3 Enhancements. 
  
 (a) The parties hereto acknowledge that CryoCor intends to commit
such resources and personnel as CryoCor shall deem appropriate to design and make such modifications, improvements and enhancements to the Cryogen Intellectual Property Rights and/or Licensed Products as shall be necessary in order to meet
CryoCor’s customers’ requirements. Beginning on the date hereof and continuing until [...***...], CryoCor covenants and agrees to promptly (i) notify Cryogen of each such modification, improvement or enhancement and (ii) prepare and
provide to Cryogen a Written Idea Memorandum with respect to each such modification, improvement or enhancement, in each case, upon the discovery or development of any such modification, improvement or enhancement. With respect to any such
modification, improvement or enhancement that is a CryoCor Enhancement (as defined in Section 1.3 hereof) or a Joint Enhancement (as defined in Section 1.13 hereof), CryoCor does further covenant and agree to provide to Cryogen access
to all drawings, specifications, technology and know-how related to such CryoCor Enhancement or Joint Enhancement, so as to enable Cryogen to fully use and exploit such CryoCor Enhancement and Joint Enhancement pursuant to Sections 2.2 and
2.3 hereof. CryoCor shall own all CryoCor Enhancements and shall have full rights as the owner thereof to fully use and exploit the CryoCor Enhancements in whatever manner it shall deem appropriate, subject to Cryogen’s rights, as
granted pursuant to Sections 2.2 and 2.3 hereof, to fully use and exploit the CryoCor Enhancements in whatever manner it shall deem appropriate within the Cryogen Fields. 
  
 (b) The parties hereto acknowledge that Cryogen may commit such resources and personnel as Cryogen shall deem
appropriate to design and make such modifications, improvements and enhancements to the Cryogen Intellectual Property Rights as may be necessary in order to meet Cryogen’s or its customers’ requirements. Beginning on the date hereof and
continuing until [...***...], Cryogen covenants and agrees to promptly (i) notify CryoCor of each such modification, improvement or enhancement and (ii) prepare and provide to CryoCor a Written Idea Memorandum with respect to each such
modification, improvement or enhancement, in each case, upon the discovery or development of any such modification, improvement or enhancement. With respect to any such modification, improvement or enhancement that is a Cryogen Enhancement (as
defined in Section 1.5 hereof), or a Joint Enhancement (as defined in Section 1.13 hereof), Cryogen does further covenant and agree to provide to CryoCor access to all drawings, specifications, technology and know-how related to such
Cryogen Enhancements or Joint Enhancements, so as to enable CryoCor to fully use and exploit such CryoCor Enhancements or Joint Enhancements pursuant to Section 2.1 hereof. Cryogen shall own all Cryogen Enhancements and shall have full rights
as the owner thereof to 
  

					
	 	 	12.	 	* Confidential Treatment Requested

 fully use and exploit the Cryogen Enhancements in whatever manner it shall deem appropriate, subject to CryoCor’s
rights, as granted pursuant to Section 2.1 hereof, to fully use and exploit the Cryogen Enhancements in whatever manner it shall deem appropriate within the CryoCor Field. 
  
 (c) Cryogen and CryoCor shall jointly own all Joint Enhancements and shall have equal undivided rights as the joint
owners thereof to fully use and exploit the Joint Enhancements in whatever manner they shall deem appropriate, subject to CryoCor’s rights, as granted pursuant to Section 2.1 hereof, to fully use and exploit the Cryogen Joint Enhancement
Interest in whatever manner it shall deem appropriate within the CryoCor Field, and subject to Cryogen’s rights, as granted pursuant to Sections 2.2 and 2.3 hereof, to fully use and exploit the CryoCor Joint Enhancement Interest
in whatever manner it shall deem appropriate within the Cryogen Fields. 
  
 8.4 No Waiver. Failure by either party to enforce any provision of this Agreement will not be deemed a waiver of future enforcement of that or any other provision. 
  
 8.5 Independent Contractors. The relationship of Cryogen and CryoCor established by this Agreement is that of
independent contractors, and nothing contained in this Agreement shall be construed (i) to give either party the power to direct or control the day-to-day activities of the other or (ii) to constitute the parties as partners, joint venturers,
co-owners or otherwise as participants in a joint or common undertaking. 
  
 8.6 Section Headings. The section headings contained herein are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 
  
 8.7 Interpretation. The parties agree that this Agreement shall be
fairly interpreted in accordance with its terms without any strict construction in favor of or against either party and that ambiguities shall not be interpreted against the drafting party. 
  
 8.8 Severability. If for any reason a court of competent jurisdiction
finds any provision of this Agreement, or portion thereof, to be unenforceable, that provision of the Agreement will be enforced to the maximum extent permissible so as to effect the intent of the parties, and the remainder of this Agreement will
continue in full force and effect. 
  
 8.9 Attorneys’
Fees. The prevailing party in any action to enforce the Agreement shall be entitled to recover costs and expenses including, without limitation, reasonable attorneys’ fees. 
  
 8.10 Injunctive Relief. The parties agree that a material default of the provisions of this Agreement by a party
hereto could cause irreparable injury to the other party for which monetary damages would not be an adequate remedy and such other party shall be entitled to seek equitable relief, including injunctive relief and specific performance, in addition to
any remedies it may have hereunder or at law. 
  
 8.11
Notices. Except as may be otherwise provided herein, all notices, requests, waivers and other communications made pursuant to this Agreement shall be in writing and shall be conclusively deemed to have been duly given: (a) when hand delivered to
the other party; (b) when received when sent by facsimile at the address set forth below; (c) three (3) business 
  

 13. 

 days after deposit in the U.S. mail with first class or certified mail receipt requested postage prepaid and addressed to
the other party as set forth below; or (d) the next business day after deposit with a national overnight delivery service, postage prepaid, addressed to the parties as set forth below with next-business-day delivery guaranteed, provided that the
sending party receives a confirmation of delivery from the delivery service provider. 
  

			
	 To CryoCor:

		
	 	  	 c/o MPM Asset Management LLC
 601 Gateway Blvd., Suite
300
 South San Francisco, CA 94080
 Facsimile: (650)
829-5828
 Attention: Gregory M. Ayers, M.D., Ph.D.

	
	 With copies to:

		
	 	  	 Gray Cary Ware & Freidenrich LLP
 4365 Executive
Drive, Suite 1600
 San Diego, California 92121
 Facsimile: (858)
677-1477
 Attention: Paul E. Kreutz, Esq.

	
	 To Cryogen:

	 	  	 Cryogen, Inc.
 11065 Sorrento Valley Court

San Diego, California 92121
 Facsimile: (858) 450-3187
 Attention: President

	
	 With copies to:

		
	 	  	 Brobeck, Phleger & Harrison LLP
 12390 El Camino
Real
 San Diego, California 92130
 Facsimile: (858)
720-2555
 Attention: Michael S. Kagnoff, Esq.

  
 Each person making a
communication hereunder by facsimile shall promptly confirm by telephone to the person to whom such communication was addressed each communication made by it by facsimile pursuant hereto but the absence of such confirmation shall not affect the
validity of any such communication. A party may change or supplement the addresses given above, or designate additional addresses, for purposes of this Section 8.11 by giving the other party written notice of the new address in the manner set
forth above. 
  

 14. 

 8.12 Patent Marking. 
  
 (a) CryoCor shall mark all Licensed Products made, used, sold, offered for sale, or imported under the terms of this
Agreement, and for their containers and packaging, in accordance with the applicable patent marking laws and regulations of the jurisdiction in which such Licensed Products are made, sold, offered for sale or imported. 
  
 (b) Cryogen shall mark all products utilizing any of the CryoCor
Enhancements made, used, sold, offered for sale, or imported under the terms of this Agreement, and or their containers and packaging, in accordance with the applicable patent marking laws and regulations of the jurisdiction in which such products
are made, sold, offered for sale or imported. 
  
 8.13 Entire
Agreement. This Agreement, including any Exhibits attached hereto, which are hereby incorporated by reference, constitutes the entire understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements or
representations, oral or written, regarding such subject matter. This Agreement may not be modified or amended except in a writing signed by a duly authorized representative of both parties. 
  
 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by
their duly authorized representatives: 
  

									
	CRYOGEN INC.	 	 	 	CRYOCOR, INC.
					
	By:	 	 /s/    DAVID R. MURRAY

	 	 	 	By:	 	 /s/    GREGORY M. AYERS

					
	Name:	 	 David R. Murray

	 	 	 	Name:	 	 Gregory M. Ayers

					
	Title:	 	 President & CEO

	 	 	 	Title:	 	 President & CEO

  
  

 15. 

 EXHIBIT A 
  

CRYOGEN INTELLECTUAL PROPERTY RIGHTS 
  

									
	 TITLE

	 	 DOCKET
 NUMBER

	 	 PUB./
 PATENT #

	 	 TYPE

	 	 FILING/
 ISSUE DATE

	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	 	 	 	 	 	 	 	 	 

 [...***...] 
  

					
	 	 	1.	 	* Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]